gemcitabine and Drug Hypersensitivity
gemcitabine has been researched along with Drug Hypersensitivity in 10 studies
Research
Studies (10)
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (20.00) | 29.6817 |
2010's | 8 (80.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors
Authors | Studies |
---|---|
Mahdi, H; Maurer, K; Michener, C; Rose, PG | 1 |
Amorin, S; Brice, P; Deau, B; Guillermin, Y; Harel, S; Lebras, L; Michallet, AS; Reynes, C; Salles, G; Subtil, F | 1 |
Asami, Y; Iiba, M; Kitagawa, R; Kondo, K; Sato, N; Sugita, M; Tadauchi, K; Tsunoda, H; Uenoyama, A | 1 |
Arenare, L; Bergamini, A; Cecere, SC; Della Pepa, C; Di Napoli, M; Facchini, G; Gargiulo, P; Mangili, G; Pignata, S; Pisano, C; Rossetti, S; Tambaro, R | 1 |
Burris, HA; Greco, FA; Hainsworth, JD; Inhorn, RC; Lane, CM; Reeves, J; Rubinsak, J; Spigel, DR; Thompson, DS; Vazquez, ER; Webb, C | 1 |
Chakerian, P; Kaley, K; Lamb, L; Saif, MW | 1 |
Pineda de la Losa, F; Prieto García, A | 1 |
Chang, YS; Cho, SH; Kang, SY; Kim, JH; Kim, MH; Kim, MY; Kim, SH; Kim, YJ; Lee, JS; Lee, KW; Lee, SY; Min, KU; Song, WJ; Yang, MS | 1 |
Needle, MN | 1 |
Ardavanis, A; Baziotis, N; Gerasimidis, G; Rigatos, G; Tryfonopoulos, D; Yiotis, I | 1 |
Reviews
1 review(s) available for gemcitabine and Drug Hypersensitivity
Article | Year |
---|---|
Safety experience with IMC-C225, an anti-epidermal growth factor receptor antibody.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Cisplatin; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Drug Eruptions; Drug Hypersensitivity; Drug Interactions; Gemcitabine; Head and Neck Neoplasms; Humans; Irinotecan; Pancreatic Neoplasms | 2002 |
Trials
1 trial(s) available for gemcitabine and Drug Hypersensitivity
Article | Year |
---|---|
Phase II study of cetuximab, docetaxel, and gemcitabine in patients with previously untreated advanced non-small-cell lung cancer.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cetuximab; Deoxycytidine; Disease-Free Survival; Docetaxel; Drug Hypersensitivity; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Taxoids; Tennessee; Treatment Outcome | 2010 |
Other Studies
8 other study(ies) available for gemcitabine and Drug Hypersensitivity
Article | Year |
---|---|
Universal tolerance of nab-paclitaxel for gynecologic malignancies in patients with prior taxane hypersensitivity reactions.
Topics: Adult; Aged; Albumins; Anemia; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Cisplatin; Deoxycytidine; Docetaxel; Drug Hypersensitivity; Female; Gemcitabine; Genital Neoplasms, Female; Humans; Middle Aged; Nervous System Diseases; Neutropenia; Paclitaxel; Retreatment; Retrospective Studies; Taxoids; Thrombocytopenia | 2017 |
Sequential combination of gemcitabine, vinorelbine, pegylated liposomal doxorubicin and brentuximab as a bridge regimen to transplant in relapsed or refractory Hodgkin lymphoma.
Topics: Adolescent; Adult; Anemia; Antineoplastic Agents; Brentuximab Vedotin; Deoxycytidine; Doxorubicin; Drug Administration Schedule; Drug Hypersensitivity; Female; Gemcitabine; Hodgkin Disease; Humans; Immunoconjugates; Male; Neutropenia; Polyethylene Glycols; Recurrence; Remission Induction; Retrospective Studies; Survival Analysis; Treatment Outcome; Vinblastine; Vinorelbine | 2015 |
[A Patient with Recurrent Ovarian Cancer Who Was Hypersensitive to Carboplatin Exhibited Complete Response to Gemcitabine and Nedaplatin].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Drug Hypersensitivity; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Ovarian Neoplasms; Recurrence | 2015 |
Cisplatin can be safely administered to ovarian cancer patients with hypersensitivity to carboplatin.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Deoxycytidine; Doxorubicin; Drug Hypersensitivity; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Polyethylene Glycols; Retrospective Studies | 2017 |
First case report associating gemcitabine with hypersensitivity reaction in a patient with pancreatic cancer.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Deoxycytidine; Drug Hypersensitivity; Female; Gemcitabine; Humans; Middle Aged; Pancreatic Neoplasms | 2010 |
Immunoglobulin E-mediated severe anaphylaxis to paclitaxel.
Topics: Anaphylaxis; Antineoplastic Combined Chemotherapy Protocols; Asthma; Cisplatin; Deoxycytidine; Drug Hypersensitivity; Dyspnea; Epitopes; Female; Gemcitabine; Humans; Hypersensitivity, Immediate; Hypotension; Immunoglobulin E; Middle Aged; Neoplasms; Paclitaxel; Pulmonary Atelectasis; Remission Induction; Skin Tests | 2010 |
Hypersensitivity reactions to oxaliplatin: clinical features and risk factors in Koreans.
Topics: Aged; Anaphylaxis; Anti-Inflammatory Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Dexamethasone; Drug Eruptions; Drug Hypersensitivity; Female; Fluorouracil; Gemcitabine; Glucocorticoids; Histamine H1 Antagonists; Humans; Hydrocortisone; Leucovorin; Male; Middle Aged; Multivariate Analysis; Neoplasms; Organoplatinum Compounds; Oxaliplatin; Prevalence; Republic of Korea; Retrospective Studies; Risk Factors | 2012 |
Non-allergic nature of docetaxel-induced acute hypersensitivity reactions.
Topics: Administration, Oral; Adult; Blood Pressure; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Deoxycytidine; Docetaxel; Doxorubicin; Drug Hypersensitivity; Female; Gemcitabine; Histamine; Histamine Antagonists; Humans; Hypersensitivity, Immediate; Infusions, Intravenous; Male; Methylprednisolone; Middle Aged; Paclitaxel; Premedication; Serine Endopeptidases; Tachycardia; Taxoids; Time Factors; Tryptases | 2004 |